SCHEMBL1770128

SCHEMBL1770128

CC(=O)Nc1nnc(SCC(=O)C23CC4CC(CC(C4)C2)C3)s1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 2/20 0.69
▸ NPC1 O15118 3/20 0.64
▸ RAB9A P51151 2/20 0.57
▸ NTSR1 P30989 1/20 0.57
▸ ALDH1A1 P00352 5/20 0.51
▸ APOBEC3A P31941 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ APOBEC3G Q9HC16 1/20 0.49
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ LMNA P02545 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770047 0.87 HSD11B1 (0.64) HSD11B1NPC1RAB9ANTSR1ALDH1A1
SCHEMBL1770040 0.82 HSD11B1 (1.00) HSD11B1NPC1RAB9AALDH1A1KMT2A
SCHEMBL1770105 0.81 HSD11B1 (0.78) HSD11B1NPC1RAB9ANTSR1ALDH1A1
SCHEMBL1769899 0.78 HSD11B1 (0.73) HSD11B1NPC1RAB9AALDH1A1NPSR1
SCHEMBL1770139 0.78 HSD11B1 (0.72) HSD11B1NPC1RAB9ANTSR1ALDH1A1
SCHEMBL1770064 0.76 NPC1 (0.49) HSD11B1NPC1RAB9ANTSR1NPSR1
SCHEMBL1770485 0.75 HSD11B1 (0.70) HSD11B1NPC1RAB9ANTSR1NPSR1
SCHEMBL5181389 0.72 SMN1; SMN2 (0.69) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL11117150 0.71 SMN1; SMN2 (0.58) NPC1RAB9AALDH1A1APOBEC3ANPSR1
SCHEMBL3319841 0.71 GAA (0.57) HSD11B1NPC1RAB9AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 — — US disclosed
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE STERIX LIMITED (GB) 2011-05-12 — — US disclosed
EP-2257528-A2 1 IBETA-HYDROXYSTEROID DEHYDROGENASE INHIBITORS Sterix Limited (GB) 2010-12-08 — — EP disclosed
WO-2009106817-A2 COMPOUND STERIX LIMITED (GB) 2009-09-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112151-A1 COMPOUND CAPABLE OF INHIBITING 11-BETA HYDROXYSTERIOD DEHYDROGENASE HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885NPC1 1692/4885RAB9A 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback